Advertisement
MGTX vs PRTA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MGTX is a StrongBuy and PRTA is a Hold.
MGTX's RSI Oscillator climbs out of oversold territory
The RSI Indicator for MGTX moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In 25 of the 26 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 62 of 68 cases where MGTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for MGTX just turned positive on October 21, 2026. Looking at past instances where MGTX's MACD turned positive, the stock continued to rise in 34 of 40 cases over the following month. The odds of a continued upward trend are 85%.
Following a +7.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGTX advanced for three days, in 212 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
MGTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
MGTX moved below its 50-day moving average on September 21, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MGTX crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for MGTX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. MGTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.353) is normal, around the industry mean (2.973). P/E Ratio (10.978) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (2.715) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
PRTA's RSI Oscillator climbs out of oversold territory
The RSI Oscillator for PRTA moved out of oversold territory on September 17, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 23 of the 27 cases the stock moved higher. This puts the odds of a move higher at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +1.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRTA advanced for three days, in 201 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PRTA as a result. In 81 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for PRTA turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 42 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
PRTA moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PRTA crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRTA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for PRTA entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.476) is normal, around the industry mean (2.973). P/E Ratio (-10.185) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (8.104) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. PRTA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
MGTX | PRTA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 16 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 85 Overvalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 16 | 94 | |
PRICE GROWTH RATING 1..100 | 63 | 72 | |
P/E GROWTH RATING 1..100 | 65 | 34 | |
SEASONALITY SCORE 1..100 | 34 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PRTA's Valuation (15) in the Biotechnology industry is significantly better than the same rating for MGTX (85). This means that PRTA’s stock grew significantly faster than MGTX’s over the last 12 months.
PRTA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MGTX (100). This means that PRTA’s stock grew similarly to MGTX’s over the last 12 months.
MGTX's SMR Rating (16) in the Biotechnology industry is significantly better than the same rating for PRTA (94). This means that MGTX’s stock grew significantly faster than PRTA’s over the last 12 months.
MGTX's Price Growth Rating (63) in the Biotechnology industry is in the same range as PRTA (72). This means that MGTX’s stock grew similarly to PRTA’s over the last 12 months.
PRTA's P/E Growth Rating (34) in the Biotechnology industry is in the same range as MGTX (65). This means that PRTA’s stock grew similarly to MGTX’s over the last 12 months.
| MGTX | PRTA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 4 days ago 85% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 81% |
| Momentum ODDS (%) | N/A | 1 day ago 85% |
| MACD ODDS (%) | 1 day ago 85% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 82% | 1 day ago 87% |
| Advances ODDS (%) | 3 days ago 83% | 3 days ago 74% |
| Declines ODDS (%) | 1 day ago 82% | 10 days ago 86% |
| BollingerBands ODDS (%) | 1 day ago 90% | N/A |
| Aroon ODDS (%) | 1 day ago 80% | 1 day ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MGTX’s FA Score shows that 1 FA rating(s) are green while PRTA’s FA Score has 1 green FA rating(s).
- MGTX’s FA Score: 1 green, 4 red.
- PRTA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MGTX’s TA Score shows that 5 TA indicator(s) are bullish while PRTA’s TA Score has 3 bullish TA indicator(s).
- MGTX’s TA Score: 5 bullish, 4 bearish.
- PRTA’s TA Score: 3 bullish, 6 bearish.
Price Growth
MGTX (@Biotechnology) experienced а -1.21% price change this week, while PRTA (@Biotechnology) price change was -2.94% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
MGTX is expected to report earnings on Nov 12, 2026.
PRTA is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement